# Vaccine–Autism Claims and Vaccine Avoidance

Avoiding routine childhood vaccination has no demonstrated autism-prevention benefit; loss of pathogen-specific protection increases infection risk, while genuine vaccine adverse events require separate assessment.

Overall Α follows preregistered primary SC3: avoiding eligible routine vaccination has no verified autism-prevention/net-health benefit in the examined originals. SC1 and SC2 are also Α because the set establishes no credible reproducible positive clinical vaccine-ASD association; restricted toxicity findings are retained without importing their inference into human ASD. Separate SC4 reaches Η through randomized antigen-specific prevention plus independently structured exposure/refusal/outbreak evidence. The harm score does not itself assign the nominal benefit score.

Baseline eligibility, clinical contraindications, age, formulation, dose, familial risk, exposure opportunity and follow-up horizon are determined before outcomes. Autism subgroups are not defined afterward as vaccine responders. The diagnosis is distinct from tics, cognitive test scores, cell ROS and primate imaging. Breakthrough infection, waning protection and rare adverse reactions remain within analysis; known contraindications are outside the registered eligible population rather than excluded after harm.